PHASE I/II STUDY OF PACLITAXEL CHEMOTHERAPY IN RECURRENT MALIGNANT GLIOMA

本II期研究的目的是研究 影响和最大耐受剂量的药物紫杉醇（紫杉醇）在 治疗复发性恶性胶质瘤患者。 所有患者将被 在泰素输注前使用地塞米松进行预先给药， 苯海拉明和雷尼替丁或西咪替丁治疗前。的 药代动力学研究的目的是确定 每3小时输注一次后达到的紫杉醇浓度 直至记录到肿瘤进展或总共12次输注。

The purpose of this Phase II study is to study the effectiveness, side effects & maximum tolerated dose of the drug Paclitaxel (Taxol) in treating patients with recurrent malignant glioma. All patients will be premedicated prior to Taxol infusion using the drugs Dexamethasone, Diphenhydramine & Ranitidine or Cimetidine prior to treatment. The objective of the pharmacokinetics studies will be to determine the concentration of paclitaxel achieved after a 3-hour infusion once every 3 weeks until documented tumor progression or total of 12 infusions.